Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study investigating the safety and efficacy of PXT3003 for CMT1A in children.

Trial Profile

A clinical study investigating the safety and efficacy of PXT3003 for CMT1A in children.

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Baclofen/naltrexone/sorbitol (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Jan 2019 According to a Pharnext media release, the company is planning to initiate a Phase 3 trial with pediatric PXT3003 by the end of 2019.
    • 16 Jul 2018 New trial record
    • 10 Jul 2018 According to a Pharnext media release, the European Medicines Agency (EMA) has agreed with its pediatric investigation plan (PIP) for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top